Introduction
============

There is growing attention in regard to health disorders in men because advanced age of this population is associated with numerous health problems. Recently, a distinct rise in the incidence of psychological disturbances has been noted among middle-aged and elderly men,[@b1-cia-10-1381] thus indicating an urgent need for additional studies to investigate this population. One of the conditions associated with aging males is the decreasing of testosterone levels by 1%--2% per year after the age of 40 years.[@b2-cia-10-1381] The prevalence of "biochemical hypogonadism" is high: 23.3% in 40-year-old to 79-year-old men from the European Male Ageing Study;[@b3-cia-10-1381] but this does not necessarily mean clinical hypogonadism because the majority of men with low testosterone levels remain asymptomatic.[@b4-cia-10-1381] However, some aging men do develop symptomatic hypogonadism, which is associated with diffuse symptoms, such as sexual dysfunction, metabolic disorders, overall dissatisfaction, as well as increasing emotional disturbances, moodiness, irritability, nervousness, depression, fatigability, poor concentration, and deteriorating memory. The combination of low testosterone level and an array of the above symptoms has been denoted variously, including andropausal syndrome (AS) or late-onset hypogonadism (LOH).[@b5-cia-10-1381] The diagnosis of LOH is based on clinical symptoms associated only with sexual functions and low testosterone levels, while AS refers to a clinical syndrome with characteristic psychological, sexual, and somatovegetative signs and symptoms usually attributed to the age-related decline in circulating testosterone, dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor 1 (IGF-1).[@b6-cia-10-1381]

Prediabetes (PD) is the condition in which the patients have slight increase in blood glucose concentrations than the normal levels but they are not said to be diabetic. Criteria for diagnosis of PD according to the American Diabetes Association (ADA) are as follows: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and/or glycated hemoglobin (HbA~1c~) levels ranging from 5.7% to 6.4%.[@b7-cia-10-1381] PD status is considered a risk factor for the further development of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).[@b8-cia-10-1381] The prevalence of PD in Poland is one of the highest in the world; approximately 16% of the population is estimated to have IGT and by the year 2035, the number of people with IGT is projected to increase to \~19%.[@b9-cia-10-1381]

Subnormal testosterone concentrations in T2DM, described in 2004,[@b10-cia-10-1381] are present in 25%--40% of patients.[@b11-cia-10-1381] Patients with T2DM have been recognized to have a higher prevalence of major depressive disorders and depressive symptoms than the general population.[@b12-cia-10-1381] In our previous study,[@b13-cia-10-1381] we described the high prevalence of testosterone deficiency and LOH among a population of Polish men with PD, but the prevalence of other anabolic hormone deficiency in patients with PD is unknown and probably may have several consequences, such as depressive symptoms, low quality of life, and sexual dysfunctions. Only a few studies have demonstrated relationships between anabolic hormones, sexual functions, and IFG[@b14-cia-10-1381] or PD[@b15-cia-10-1381] in men.

Therefore, in this study, we aimed to compare the Self-rating Depression Scale (SDS) and the Aging Males' Symptoms (AMS) rating scale between patients with PD and a control group, as well as to investigate the clinical and hormonal determinants of the severity of these symptoms in middle-aged and elderly men with PD.

Materials and methods
=====================

Study population
----------------

This study was performed at the Department of Internal Diseases, Diabetology and Endocrinology, Medical University of Warsaw, Poland, in patients attending the outpatient clinic for glucose metabolism disorders. The inclusion criteria were 1) a laboratory-confirmed PD, 2) age 40--80 years, and 3) no history of depression. The exclusion criteria were as follows: 1) diabetes mellitus type 1 or 2; 2) conditions that contribute to sexual dysfunction, such as history of surgery in the pelvic cavity, hyperprolactinemia, and thyroid function disturbances; 3) recent or current testosterone replacement, androgen deprivation therapy, or any hormonal treatment, either during the study or in history; and 4) lack of informed written consent. We recruited 196 consecutive patients with PD (aged between 40 years and 80 years) from the outpatient clinic. In addition, as a control group, 184 healthy men, matched by age and with a fasting plasma glucose (FPG) \<5.55 mmol/L (100 mg/dL) and HbA~1c~ \<5.7%, were also included. This study was approved by the local Research Ethics Committee and was conducted in accordance with the Declaration of Helsinki; informed consent was obtained from all participants.

PD was diagnosed in patients with IFG ranging from 100 mg/dL to 125 mg/dL (5.6--6.9 mmol/L) and 2-hour glucose concentration in the oral glucose tolerance test (OGTT) of \<140 mg/dL (\<7.8 mmol/L) or in patients with IGT (2-hour glucose concentration in OGTT ranging from 140 mg/dL to 200 mg/dL or 7.8--11.0 mmol/L) or in patients with HbA~1c~ ranging from 5.7% to 6.4%.[@b7-cia-10-1381] Because PD is a transitory state with many individuals on repeated testing showing blood glucose in the normal range, FPG and OGTT measurements were repeated after 2--3 weeks and reevaluated. The diagnosis of metabolic syndrome (MetS) was based on the following criteria: waist circumference ≥94 cm and any two of the following: triglycerides ≥150 mg/dL, high-density lipoprotein (HDL)-cholesterol \<40 mg/dL, blood pressure ≥130/85 mmHg, and FPG ≥100 mg/dL.[@b16-cia-10-1381] Height, weight, and waist circumference were measured and body mass index (BMI) was calculated. Obesity was defined as a BMI of 30 kg/m^2^ or more. CVD was defined as coronary artery disease, congestive heart failure, or arrhythmia. Hypertension and chronic obstructive pulmonary disease were also considered to be present if the participant reported having received the diagnosis or if he/she was receiving medication for the condition.

Assessment of depressive and andropausal symptoms
-------------------------------------------------

Subjects filled out a self-administered questionnaire. Depressive symptoms were assessed by means of SDS.[@b17-cia-10-1381] The SDS consists of ten negatively worded items and ten positively worded items on symptoms of depression. The level of depression was classified as normal (20--29), mild (30--39), moderate (40--49), and severe (≥50). Data on the intensity of andropausal symptoms were assessed using the AMS rating scale.[@b18-cia-10-1381] The AMS scale includes 17 symptoms divided into three groups: psychological (discouraged, depressed, irritable, anxious, and nervous); sexual (disturbed potency, impaired erectility, problems with libido, decrease in beard growth, and feeling of "having passed the zenith of life"); and somatovegetative (joint and muscle complaints, sweating, need for more sleep, sleep disturbances, weakness, exhaustion, and impaired well-being). The intensity of each symptom was rated between one (low) and five points (high). We analyzed the severity of the three subgroups of andropausal symptoms (three subscores for each cluster) and the total severity of andropausal symptoms (total AMS score, sum of three subscores). AS was diagnosed if the total AMS score was 50 points or higher.[@b18-cia-10-1381] In our study, we did not investigate the occurrence of LOH, which is diagnosed in patients with symptoms of testosterone deficiency such as low libido, diminished frequency of morning erections, and erectile dysfunctions, as well as decreased testosterone levels.[@b5-cia-10-1381]

Laboratory measurements
-----------------------

In all men with PD, venous blood samples were obtained between 8 am and 10 am. After centrifugation, the serum was collected and frozen at −70°C until analysis. FPG was measured with the enzymatic method using BIOSEN 5040 analyzer (EKF-Diagnostic GmbH, Germany), HbA~1c~ with the high-performance liquid chromatography method using Variant analyzer (Bio-Rad Laboratories Inc, USA). HbA~1c~ values were expressed as percentage according to the National Glycohemoglobin Standardization Program. The serum levels of total testosterone (TT), DHEAS, estradiol (E2), and IGF-1 were measured with immunometric assays (Immulite 2000 and RIA CAC; Siemens Medical Solution, Malvern, PA, USA) and expressed in nanomoles per liter for TT, picograms per milliliter for E2, and nanograms per milliliter for DHEAS and IGF-1 (to convert the values for DHEAS to micromoles per liter, multiply by 0.00271; for converting IGF-1 values to nanomoles per liter, multiply by 0.131; and for converting E2 values to picomoles per liter, multiply by 3.671). To estimate the circulating fraction of free testosterone, we measured the serum level of sex hormone-binding globulin (SHBG) using an immunoassay (Diagnostic Products Corp, San Francisco, CA, USA), and SHBG was expressed in nanomoles per liter. The serum level of calculated free testosterone (cFT), expressed in nanomoles per liter, was calculated with the validated equation of Vermeulen et al.[@b19-cia-10-1381]

Statistical analysis
--------------------

Statistical analyses were performed using the STATISTICA 9.1 data analysis software system (StatSoft, Tulsa, OK, USA). Most continuous variables had a normal distribution and were expressed as a mean ± standard deviation of the mean. The intergroup differences were tested using the *t*-test for unpaired samples. Serum DHEAS had a skewed distribution, so they were log-transformed to normalize their distribution, expressed as a median with lower and upper quartiles, and the intergroup differences were tested using the *t*-test for unpaired samples for the normalized values. Categorized variables were expressed as a number and a percentage, and the intergroup differences were tested using the *χ*^2^ test. The relationships between andropausal and depressive symptom scores and various factors, including age, BMI, and HbA~1c~ in men with PD were examined by Pearson's correlation analyses. Univariable and multivariable linear and logistic regression analyses were applied to establish variables determining the severity of andropausal symptoms (subscores for psychological, sexual, and somatovegetative symptoms, as well as a total AMS score) and depression symptoms, as well as the variables associated with the higher prevalence of AS. Regression analyses were performed separately in middle-aged (40--59 years) and elderly (60--80 years) age groups of men with PD. In the univariable analyses, as the potential determinants of the severity of andropausal and depression symptoms and as the potential risk factors for the higher prevalence of AS, we included the following: age, BMI, HbA~1c~, total cholesterol, TT, cFT, DHEAS, IGF-1, and E2, as well as comorbidities such as CVD, hypertension, and MetS. During the construction of multivariable models, we included all variables that had been shown to be significant (*P*\<0.05) determinants in the univariable analyses. A *P*-value \<0.05 was considered statistically significant.

Results
=======

A total of 196 men with PD (mean age: 58±4 years) and 184 healthy men (mean age: 61±5 years) were evaluated in this study. In the control group, we observed 98 men aged 40--59 years (mean BMI: 28.6±4.7 kg/m^2^) and 86 men aged 60--80 years (mean BMI: 30.8±4.3 kg/m^2^). The baseline characteristics of the men with PD are shown in [Table 1](#t1-cia-10-1381){ref-type="table"}. Patients with PD aged from 60 years to 80 years had lower TT, cFT, and DHEAS levels (*P*\<0.001, *P*\<0.005, and *P*\<0.01, respectively) and higher E2 levels and BMI (both *P*\<0.05). We observed also statistically significant differences in glucose metabolism parameters between the prediabetic groups. Men with PD aged 60--80 years had higher HbA~1c~, FPG, and glucose levels in the 2-hour OGTT (*P*\<0.02, *P*\<0.001, and *P*\<0.05, respectively). In addition, total cholesterol and uric acid levels were higher in elderly men with PD, while HDL-cholesterol concentrations were lower in this subgroup of prediabetic patients (all *P*\<0.05). Men with PD aged 60--80 years also presented with more common hypertension and CVD (*P*\<0.01 and *P*\<0.001, respectively), but percentage of current smokers was lower in this age group (*P*\<0.05).

The prevalence of AS in men with PD was significantly higher than in healthy men (35% vs 11%, respectively; *P*\<0.001). Analysis of investigated men after dividing by the age revealed that the prevalence of AS in patients with PD aged 40--59 years was higher compared with that in healthy peers (29% vs 9%, respectively; *P*\<0.001) and that the prevalence of AS in men with PD aged 60--80 years was statistically significantly higher than that observed in healthy peers (43% vs 36%, respectively; *P*\<0.05) ([Figure 1](#f1-cia-10-1381){ref-type="fig"}). Among men with PD, the prevalence of AS was significantly higher in subjects aged from 60 years to 80 years when compared with those aged from 40 years to 59 years (43% vs 29%, respectively; *P*\<0.001) ([Table 1](#t1-cia-10-1381){ref-type="table"}).

The analysis of severity of andropausal symptoms revealed that in the middle-aged group (40--59 years), the severity of sexual (*P*\<0.001), psychological (*P*\<0.002), and all andropausal symptoms (*P*\<0.001) was greater in prediabetic men compared with the same in healthy peers ([Figure 2A](#f2-cia-10-1381){ref-type="fig"}). In the elderly group (60--80 years), the severity of sexual, somatovegetative, and all andropausal symptoms was similar in men with PD and healthy peers, while severity of psychological symptoms was greater in elderly men (*P*\<0.01) ([Figure 2B](#f2-cia-10-1381){ref-type="fig"}). Among men with PD, the severity of sexual, psychological, and all andropausal (but not somatovegetative) symptoms was higher in the elderly group compared with the middle-aged group of patients with PD (all *P*\<0.001) ([Table 1](#t1-cia-10-1381){ref-type="table"}).

We observed that the severity of depressive symptoms in all men with PD was significantly higher, when compared with healthy men (38.2±7.2 vs 33.5±5.7, respectively; *P*\<0.001). We also showed that the severity of depressive symptoms in the middle-aged group of prediabetic men was significant lower than that observed in elderly patients with PD (36.7±7.7 vs 42.5±7.2, respectively; *P*\<0.002) ([Table 1](#t1-cia-10-1381){ref-type="table"}). We also showed that the severity of depressive symptoms in the middle-aged men with PD was significantly greater than that in healthy peers (36.7±7.7 vs 27.8±6.8, respectively; *P*\<0.001), while the severity of depressive symptoms in elderly prediabetic and healthy men was similar (42.5±7.2 vs 39.9±6.9, respectively) ([Figure 2A and B](#f2-cia-10-1381){ref-type="fig"}).

Analysis of correlations between AMS (total) score and SDS score, as well as the clinical and laboratory variables, in all patients with PD (n=196) revealed that there were only negative, statistically significant correlations between HbA~1c~ and AMS total score (*r*=−0.3145; *P*=0.02). We did not observe any additional significant correlations between the analyzed variables, including age and BMI ([Table 2](#t2-cia-10-1381){ref-type="table"}).

In patients with PD aged from 40 years to 59 years, in multivariable linear regression models, the more severe somatovegatative symptoms were independently associated with low serum TT, low cFT, low IGF-1, and high HbA~1c~ levels, as well as with presence of MetS; the more severe sexual symptoms were associated with low TT, low cFT, high HbA~1c~, and presence of CVD; the more severe psychological symptoms were associated with low cFT, low IGF-1, and presence of CVD (all *P*\<0.05); and the more severe andropausal symptoms (in total) were associated with low cFT (*P*\<0.05) ([Table 2](#t2-cia-10-1381){ref-type="table"}). The more severe depression symptoms were associated with low TT, low DHEAS, and the presence of CVD (all *P*\<0.05) ([Table 3](#t3-cia-10-1381){ref-type="table"}). In multivariable logistic regression models, the following variables were independently associated with the higher prevalence of AS in middle-aged men: serum cFT (odds ratio \[OR\]: 0.66, confidence interval \[CI\]: 0.42--0.79; *P*\<0.05) and IGF-1 (OR: 1.21, CI: 1.03--1.31; *P*\<0.05) ([Table 4](#t4-cia-10-1381){ref-type="table"}). In patients with PD aged from 60 years to 80 years, in multivariable linear regression models, the more severe somatovegetative symptoms were independently associated with low cFT, low DHEAS, and presence of CVD and MetS; the more severe sexual symptoms with low TT, low cFT, high HbA~1c~, and the presence of CVD and MetS; the more severe psychological symptoms with low cFT, low IGF-1, and the presence of CVD; and the more severe andropausal symptoms (in total) were associated with low TT and low DHEAS (all *P*\<0.05) ([Table 2](#t2-cia-10-1381){ref-type="table"}). The more severe depression symptoms were associated with low cFT, low DHEAS, and the presence of CVD (all *P*\<0.05) ([Table 3](#t3-cia-10-1381){ref-type="table"}). In multivariable logistic regression models, the following variables were independently associated with the higher prevalence of AS in elderly men: serum TT (OR: 1.01, CI: 0.75--1.34; *P*\<0.05) and DHEAS (OR: 1.98, CI: 1.43--4.12; *P*\<0.05) ([Table 4](#t4-cia-10-1381){ref-type="table"}).

Discussion
==========

In this study, we investigated the prevalence and severity of andropausal and depressive symptoms in men with PD and the clinical and hormonal determinants of the severity of these symptoms in middle-aged (40--69 years) compared with elderly (50--60 years) men with PD. To achieve these goals, we used the AMS rating scale and SDS.

There are three major findings arising from the present study. First, AS was very common in male patients with PD aged 40--80 years. The prevalence of AS in patients with PD aged 40--59 years waŝ3.5 times higher compared with that in control healthy peers (31% vs 9%, respectively), and the prevalence of AS in men with PD aged 60--80 years was higher than that in healthy peers (44% vs 36%, respectively). Among the men with PD, the prevalence of AS was significantly higher in the elderly when compared with middle-aged men (43% vs 29%, respectively). These results allow to propose that the occurrence of AS (except for psychological symptoms) may be accelerated in patients with PD. Second, the severity of almost all (except somatovegetative) andropausal symptoms in the younger patients was greater in prediabetic men compared with the same in healthy men. In contrast, in the elderly group with PD, the severity of only the psychological symptoms was greater than that observed in healthy peers. We observed also that the severity of depressive symptoms in prediabetic men with no history of depression was higher than in healthy men and that the severity of depressive symptoms in the middle-aged men with PD was lower than that in elderly men with PD. It appears that the higher severity of andropausal and depressive symptoms in patients with PD is associated mainly with metabolic disorders because we did not demonstrate significant correlations between age and both AMS and SDS scores in all groups of patients with PD. Third, in regression analyses, we demonstrated that hormonal determinants of andropausal and depressive symptoms are different in middle-aged and elderly men with PD. In middle-aged men, the more severe andropausal symptoms (in total) were associated with low cFT, the more severe depression symptoms were associated with low TT and low DHEAS, while the higher prevalence of AS was independently associated with serum cFT and IGF-1. In elderly men, the more severe andropausal symptoms (in total) were associated with low TT and low DHEAS, the more severe depression symptoms were associated with low cFT and low DHEAS, while the higher prevalence of AS was independently associated with serum TT and DHEAS.

The prevalence of PD in Poland is one of the highest in the world, with \~16% of the population being estimated to have IGT or IFG;[@b9-cia-10-1381] therefore, any disorders associated with PD, especially depression and impaired quality of life, are a serious public health problem in Poland. We have previously shown[@b13-cia-10-1381] that among prediabetic men, LOH was diagnosed in 30% of patients and only in 14% of control group. We also showed inverse relationships between erectile function and cFT levels. These results indicate that PD may have influence on sexual health in men and overall quality of life and mood and that these relationships may be associated with sex hormone levels. The influence of other anabolic hormones, such as DHEAS and IGF-1, on andropausal symptoms in patients with PD is still unknown. Only a few studies have demonstrated relationships between androgens and PD in men. Corona et al[@b14-cia-10-1381] showed in 1,687 men with sexual dysfunction that 19% of men were classified as IFG and these men had severe erectile dysfunction or hypogonadism more often when compared with normoglycemic men. In the Multi-Ethnic Study of Atherosclerosis (MESA) study, Colangelo et al[@b20-cia-10-1381] showed that IFG was associated inversely with TT, DHEA, and E2 and that these correlations were significant after adjustment for age and BMI. Ho et al[@b15-cia-10-1381] demonstrated in 1,306 men that PD was diagnosed in approximately 41% of patients and was associated with an increased risk of subnormal TT compared with healthy individuals (age-adjusted OR =1.87; 95% CI), which was still significant after adjusting for age, BMI, and MetS.

These results clearly indicate that prevalence of testosterone deficiency and hypogonadism among male patients with PD is high and significant. However, the prevalence of andropausal symptoms and depression symptoms in the population of men with PD is still unknown. These symptoms have been documented in men with other chronic diseases. Tkaczyszyn et al[@b6-cia-10-1381] have shown in a population of 232 men with systolic heart failure that prevalence of AS and the severity of andropausal symptoms in men aged 40--60 years were greater than in healthy peers, while in the age group of 60--80 years, there were no differences in the prevalence of AS and the severity of andropausal symptoms compared with the healthy group. In male patients with T2DM, Corrales et al[@b21-cia-10-1381] showed high prevalence of low free testosterone and andropausal symptoms in diabetic men and positive correlation between TT and HbA~1c~ levels. Fukui et al[@b22-cia-10-1381] compared the andropausal symptom scores, such as SDS and the International Index of Erectile Function (IIEF), in 296 men with T2DM with those in healthy peers and showed that SDS and IIEF scores were statistically higher in diabetic patients.

Studies on the relationships between other anabolic hormones and glucose metabolism disturbances have been limited. Colao et al[@b23-cia-10-1381] demonstrated that IGF1 levels in the low normal range are associated with IFG in males without pituitary diseases, and Kameda et al[@b24-cia-10-1381] presented association of low DHEAS levels with the progression of male patients with PD to T2DM. These results have suggested that DHEAS and IGF-1 also play an important role in glucose metabolism in men, but their influence on andropausal symptoms in men with PD is still unknown.

As we noted earlier, PD is associated with low testosterone levels; however, the mechanism of this phenomenon is still unclear. Low levels of TT and SHBG (associated with insulin resistance) are independent risk factors in middle-aged men who later developed PD and are inversely correlated with IFG, insulin levels, and IGT.[@b1-cia-10-1381] But importantly, low testosterone is a risk factor in men who were not initially obese, and low free and bioavailable but not TT levels, after adjustment for age and adiposity, were approximately four times more likely to predict T2DM development. These findings support that the risk does not depend on adiposity.[@b25-cia-10-1381] Interestingly, men with diabetes type 1 have normal testosterone levels, which is probably due to low insulin levels in patients with diabetes type 1 and high levels in men with T2DM. There is also an inverse relationship between insulin and SHBG, and consequently, plasma levels of TT are lower in men with T2DM.[@b26-cia-10-1381] Adipose tissue produces cytokines and adipokines, of which leptin is a prominent member. Leptin receptors are present on Leydig cells and inhibit testosterone synthesis, especially in obese men with high leptin levels. In addition, high insulin levels are positively associated with high leptin levels and may contribute to low TT concentrations in patients with PD. On the other hand, hyperinsulinemia, as encountered in insulin resistance, might impair testosterone secretion directly because there are insulin receptors on the Leydig cells.[@b1-cia-10-1381],[@b27-cia-10-1381],[@b28-cia-10-1381]

Patients with T2DM are two times as likely to be depressed when compared with healthy people.[@b29-cia-10-1381] Depression among those with T2DM is associated with increased diabetes complications[@b30-cia-10-1381] and poor glycemic control.[@b31-cia-10-1381] The associations between low TT levels and depression, loss of libido, and vigor in men are well understood.[@b32-cia-10-1381] The Rancho Bernardo Study[@b33-cia-10-1381] showed that greater prevalence of depression was associated with lower (\~17%) bioavailable testosterone levels. Symptoms of hypogonadism may be also include diminished sexual desire and erectile quality, particularly in nocturnal erections, as well as changes in mood with concomitant decreases in intellectual activity and spatial orientation, fatigue, depression, and anger.[@b34-cia-10-1381],[@b35-cia-10-1381] These symptoms are the most common, and studies suggest that testosterone replacement may have an antidepressant effect in depressed patients.[@b36-cia-10-1381],[@b37-cia-10-1381]

In our study, we showed high prevalence of AS, as well as high severity of andropausal symptoms, in all male patients with PD. However, differences between middle-aged prediabetic patients and healthy peers were greater than that observed between elderly men and healthy men: in the elderly group, only the severity of the psychological symptoms was greater than that observed in healthy peers. Probably, these observations are partially associated with the fact that PD, obesity, and MetS comprise a serious disease with strong and multidirectional influence on endocrine and vascular systems, causing serious sexual and psychological symptoms, particularly disadvantaging the younger population.

Our methodological model has enabled us to investigate potential associations of hormonal milieu, including anabolic androgen deficiencies, with andropausal and depressive symptoms. The results of our study showed that different hormonal mechanisms are involved in the regulation of sexual and psychological status in middle-aged and elderly patients with PD.

It should be noted that in our study, PD was diagnosed also in patients with HbA~1c~ ranging from 5.7% to 6.4%.[@b7-cia-10-1381] Currently, an intermediate HbA~1c~ range is not considered as PD by the World Health Organization; however, the ADA definition probably indicates a wider range of subjects at risk of T2DM development, and HbA~1c~ of 5.7%--6.4% detects, in part, different individuals with intermediate hyperglycemia, compared with IFG and IGT.[@b38-cia-10-1381] It should be also emphasized that we did not investigate the severity and prevalence of LOH, which is recognized in patients with symptoms of hypogonadism and low TT or cFT levels.[@b5-cia-10-1381] We focused only on associations between andropausal and depressive symptoms in patients with PD, as well as the clinical and hormonal risk factors. Our model in no way established a causal link between anabolic hormone deficiency and PD; these conditions might simply overlap and they have probably separate pathophysiologic pathways.

Conclusion
==========

The prevalence and severity of andropausal and depressive symptoms are higher in patients with PD as compared with the same in healthy men. Hormonal determinants of these symptoms are different in middle-aged and elderly patients. Further studies are needed to establish whether androgen replacement therapy would be beneficial in prediabetic men.
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![Prevalence (%) of andropausal syndrome in men with prediabetes (n=196) and healthy men (n=184).\
**Notes:** Andropausal syndrome was diagnosed according to the AMS[@b18-cia-10-1381] and was diagnosed if the total AMS score was 50 points or higher. The intergroup differences were tested using the *χ*^2^ test.\
**Abbreviations:** AMS, Aging Males' Symptoms rating scale; PD, prediabetes.](cia-10-1381Fig1){#f1-cia-10-1381}

![Severity of andropausal symptoms (expressed as points).\
**Notes:** Severity of andropausal symptoms (according to AMS scale) and depressive symptoms (according to SDS scale) in men with PD (**A**) aged 40--59 years (n=98), and (**B**) aged 60--80 years (n=86), compared with healthy men (n=184). The intergroup differences were tested using the *t*-test for unpaired samples.\
**Abbreviations:** AMS, Aging Males' Symptoms rating scale; NS, nonsignificant; PD, prediabetes; SDS, Self-rating Depression Scale.](cia-10-1381Fig2){#f2-cia-10-1381}

###### 

Baseline characteristics of men with prediabetes divided according to age

  Clinical and laboratory variables   PD               *P*-value[\*](#tfn2-cia-10-1381){ref-type="table-fn"}                    
  ----------------------------------- ---------------- ------------------------------------------------------- ---------------- -------
  Age, years                          58±4             52±3                                                    69±4             
  TT, nmol/L                          13.8±3.7         15.7±3.2                                                11.7±3.6         0.001
  cFT, nmol/L                         0.338±0.08       0.355±0.08                                              0.315±0.08       0.005
  DHEAS, ng/mL                        529 (198--897)   689 (234--907)                                          423 (167--745)   0.01
  IGF-1, ng/mL                        89.2±41.3        93.6±44.6                                               87.4±40.8        
  LH, IU/L                            5.9±1.3          5.5±1.2                                                 6.3±1.4          
  E2, pg/mL                           29.4±9.8         28.4±11.7                                               32.6±9.7         0.05
  SHBG, nmol/L                        31.6±4.2         30.9±3.8                                                32.7±3.8         
  BMI, kg/m^2^                        29.4±4.5         28.6±4.7                                                30.8±4.3         0.05
  WC, cm                              102±7.5          101±7.6                                                 104±6.8          
  HbA~1c~, %                          6.0±0.3          5.9±0.2                                                 6.1±0.3          0.02
  FPG, mg/dL                          117±5.6          115±5.2                                                 121±6.2          0.001
  Glucose in OGTT, mg/dL              141±6.1          137±12.6                                                147±12.6         0.05
  SBP, mmHg                           129±18           125±19                                                  135±19           
  DBP, mmHg                           94±11            92±10                                                   96±11            
  Cholesterol, mg/dL                  223±43           218±41                                                  228±37           0.05
  Triglycerides, mg/dL                169±12           167±14                                                  172±14           
  HDL-cholesterol, mg/dL              36±4             39±6                                                    34±4             0.05
  LDL-cholesterol, mg/dL              147±22           142±22                                                  156±24           
  Comorbidities                                                                                                                 
  Obesity, % (n)                      71 (140)         73 (82)                                                 69 (58)          
   Current smoker, % (n)              32 (65)          36 (40)                                                 30 (25)          0.05
   Hypertension, % (n)                52 (102)         44 (49)                                                 63 (53)          0.01
   MetS, % (n)                        83 (162)         81 (91)                                                 86 (72)          
   CVD, % (n)                         26 (52)          18 (20)                                                 38 (32)          0.001
  Andropausal symptoms                                                                                                          
   Psychological, points              11.3±4.2         9.9±4.7                                                 11.6±4.9         0.05
   Sexual, points                     13.9±4.9         12.6±4.2                                                15.1±4.8         0.001
   Somatovegetative, points           17.6±5.7         18.1±5.9                                                19.2±6.2         
   All symptoms, points               42.8±13.6        40.6±13.7                                               45.9±13.9        0.001
   AS, % (n)                          35 (69)          29 (33)                                                 43 (36)          0.001
  Depressive symptoms                                                                                                           
   SDS, points                        38.2±7.2         36.7±7.7                                                42.5±7.2         0.002

**Notes:** Data are presented as a mean ± standard deviation of the mean, a median (with lower and upper quartiles) or number (percentage), where appropriate.

Indicates differences between prediabetic men 60--80 years and 40--59 years old.

**Abbreviations:** AS, andropausal syndrome; BMI, body mass index; cFT, calculated free testosterone; CVD, cardiovascular disease; DBP, diastolic blood pressure; DHEAS, dehydroepiandrosterone sulfate; E2, estradiol; FPG, fasting plasma glucose; HbA~1c~, glycated hemoglobin; HDL, high-density lipoprotein; IGF-1, insulin-like growth factor 1; LDL, low-density lipoprotein; LH, luteinizing hormone; MetS, metabolic syndrome; OGTT, oral glucose tolerance test; PD, prediabetes; SBP, systolic blood pressure; SDS, Self-rating Depression Scale; SHBG, sex hormone-binding globulin; TT, total testosterone; WC, waist circumference.

###### 

Correlations between andropausal (total) and depressive symptoms scores and clinical characteristics in 196 men with prediabetes

  Variables       AMS (total) points   SDS points            
  --------------- -------------------- ------------ -------- ------
  Age, years      −0.052               0.46         −0.081   0.31
  BMI (kg/m^2^)   0.021                0.29         −0.065   0.13
  HbA~1c~         −0.3145              0.02         0.025    0.64

**Note:** Correlations were examined using Pearson's correlation analyses.

**Abbreviations:** AMS, the Aging Males' Symptoms rating scale score; BMI, body mass index; HbA~1c~, glycated hemoglobin; SDS, the Self-rating Depression Scale score.

###### 

Parameters associated with the severity of andropausal and depressive symptoms in men with prediabetes

  Variables                                    Andropausal symptoms                               Depressive symptoms                                                                                                                                                                                                                                                                                                                                                                                                      
  -------------------------------------------- -------------------------------------------------- --------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ---------------------------------------------------
  **Men with prediabetes aged 40--59 years**                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Age, years                                   0.19                                               --                                                  0.11                                               --                                                 0.09                                               --                                                 0.11                                               --                                                 0.09                                               --
  TT, nmol/L                                   −0.26[b](#tfn7-cia-10-1381){ref-type="table-fn"}   −0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}    −0.22[c](#tfn8-cia-10-1381){ref-type="table-fn"}   --                                                 −0.19[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.09                                              --                                                 −0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}
  cFT, nmol/L                                  −0.39[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.25[c](#tfn8-cia-10-1381){ref-type="table-fn"}    −0.34[b](#tfn7-cia-10-1381){ref-type="table-fn"}   −0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.03                                              --
  DHEAS, ng/mL (ln)                            −0.24[b](#tfn7-cia-10-1381){ref-type="table-fn"}   −0.21                                               −0.06[a](#tfn6-cia-10-1381){ref-type="table-fn"}   −0.12                                              0.11[b](#tfn7-cia-10-1381){ref-type="table-fn"}    --                                                 −0.21[b](#tfn7-cia-10-1381){ref-type="table-fn"}   --                                                 −0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}
  IGF-1, ng/mL                                 0.01                                               --                                                  −0.27[b](#tfn7-cia-10-1381){ref-type="table-fn"}   −0.25[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}   0.02                                               --                                                 0.03                                               --
  E2, pg/mL                                    0.02                                               --                                                  0.07                                               --                                                 0.07                                               --                                                 0.08                                               --                                                 0.20[a](#tfn6-cia-10-1381){ref-type="table-fn"}    --
  BMI, kg/m^2^                                 0.15                                               --                                                  0.12                                               --                                                 0.02                                               --                                                 0.41[c](#tfn8-cia-10-1381){ref-type="table-fn"}    --                                                 0.05                                               --
  HbA~1c~, %                                   0.21[a](#tfn6-cia-10-1381){ref-type="table-fn"}    0.20[c](#tfn8-cia-10-1381){ref-type="table-fn"}     0.03                                               --                                                 −0.37[b](#tfn7-cia-10-1381){ref-type="table-fn"}   0.32[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.23                                               --                                                 −0.02                                              --
  Hypertension, yes vs no                      0.06                                               --                                                  0.07                                               --                                                 0.03                                               --                                                 0.03                                               --                                                 0.06                                               --
  MetS, yes vs no                              0.12                                               --                                                  0.19                                               --                                                 0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.09                                               --                                                 0.09                                               --
  CVD, yes vs no                               0.27[b](#tfn7-cia-10-1381){ref-type="table-fn"}    0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}     0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.07                                               --                                                 0.13                                               --                                                 0.31[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}
  COPD, yes vs no                              0.07                                               --                                                  0.15[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.32[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.11                                               --                                                 0.19[b](#tfn7-cia-10-1381){ref-type="table-fn"}    0.28[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.09                                               --
  **Men with prediabetes aged 60--80 years**                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Age, years                                   0.11                                               --                                                  0.34                                               --                                                 0.11                                               --                                                 0.11                                               --                                                 0.11                                               --
  TT, nmol/L                                   −0.21[b](#tfn7-cia-10-1381){ref-type="table-fn"}   --0.22[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.28[b](#tfn7-cia-10-1381){ref-type="table-fn"}   --                                                 −0.31[b](#tfn7-cia-10-1381){ref-type="table-fn"}   --                                                 −0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.20[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.17                                              --
  cFT, nmol/L                                  −0.32[a](#tfn6-cia-10-1381){ref-type="table-fn"}   --0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.26[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.31[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.09                                              --                                                 −0.52[c](#tfn8-cia-10-1381){ref-type="table-fn"}   --0.41[c](#tfn8-cia-10-1381){ref-type="table-fn"}
  DHEAS, ng/mL (ln)                            −0.25[b](#tfn7-cia-10-1381){ref-type="table-fn"}   --                                                  0.07                                               --                                                 −0.29[b](#tfn7-cia-10-1381){ref-type="table-fn"}   −0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.28[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.31[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.43[c](#tfn8-cia-10-1381){ref-type="table-fn"}   --0.38[c](#tfn8-cia-10-1381){ref-type="table-fn"}
  IGF-1, ng/mL                                 −0.12                                              --                                                  −0.24[b](#tfn7-cia-10-1381){ref-type="table-fn"}   −0.19[c](#tfn8-cia-10-1381){ref-type="table-fn"}   −0.19[b](#tfn7-cia-10-1381){ref-type="table-fn"}   --                                                 0.41                                               --                                                 0.27[a](#tfn6-cia-10-1381){ref-type="table-fn"}    --
  E2, pg/mL                                    0.12                                               --                                                  0.19                                               --                                                 0.34[c](#tfn8-cia-10-1381){ref-type="table-fn"}    --                                                 0.07                                               --                                                 0.08                                               --
  BMI, kg/m^2^                                 0.10                                               --                                                  0.02                                               --                                                 0.02                                               --                                                 0.13                                               --                                                 0.11                                               --
  HbA~1c~, %                                   0.41[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}     0.24[a](#tfn6-cia-10-1381){ref-type="table-fn"}    --                                                 0.21                                               --                                                 0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}    --                                                 0.02                                               --
  Hypertension, yes vs no                      0.08                                               --                                                  0.08                                               --                                                 0.08                                               --                                                 0.08                                               --                                                 0.03                                               --
  MetS, yes vs no                              0.21[a](#tfn6-cia-10-1381){ref-type="table-fn"}    0.19[c](#tfn8-cia-10-1381){ref-type="table-fn"}     0.19                                               --                                                 0.25[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.03                                               --                                                 0.21[b](#tfn7-cia-10-1381){ref-type="table-fn"}    --
  CVD, yes vs no                               0.36[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.22[c](#tfn8-cia-10-1381){ref-type="table-fn"}     0.41[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.18[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.42[a](#tfn6-cia-10-1381){ref-type="table-fn"}    0.27[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.03                                               --                                                 0.41[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.34[c](#tfn8-cia-10-1381){ref-type="table-fn"}
  COPD, yes vs no                              0.26[b](#tfn7-cia-10-1381){ref-type="table-fn"}    0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}     0.18[a](#tfn6-cia-10-1381){ref-type="table-fn"}    0.22[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.21[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.32[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.29[a](#tfn6-cia-10-1381){ref-type="table-fn"}    0.23[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.24[c](#tfn8-cia-10-1381){ref-type="table-fn"}    0.29[c](#tfn8-cia-10-1381){ref-type="table-fn"}

**Notes:**

*P*\<0.001;

*P*\<0.01;

*P*\<0.05; data are presented as standardized regression coefficient *β* (in both univariable and multivariable models). All variables shown to be significant determinants of the severity of andropausal symptoms in the univariable models (*P*\<0.05) were included in the multivariable models. --Indicates no data available.

**Abbreviations:** BMI, body mass index; cFT, calculated free testosterone; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DHEAS, dehydroepiandrosterone sulfate; E2, estradiol; HbA~1c~, glycated hemoglobin; IGF-1, insulin-like growth factor 1; ln, natural logarithm; MetS, metabolic syndrome; TT, total testosterone; vs, versus.

###### 

Risk factors associated with the higher prevalence of AS in men with prediabetes

  Variables           Men with AS        Men without AS                                             Unit                                         Univariable model   Multivariable model                                                 
  ------------------- ------------------ ---------------------------------------------------------- -------------------------------------------- ------------------- --------------------- ------- --------- ------ ------------ ------- ------
                      **n=33**           **n=79**                                                   **Men with prediabetes aged 40--59 years**                                                                                           
  Age, years          55±3               53±4                                                       1 year                                       0.95                0.91--1.04            2.62    0.20      --     --           --      --
  TT, nmol/L          15.1±3.1           16.1±3.4[\*](#tfn10-cia-10-1381){ref-type="table-fn"}      1 nmol/L                                     1.02                0.98--1.04            0.58    0.42      --     --           --      --
  cFT, nmol/L         0.333±0.08         0.366±0.08[\*](#tfn10-cia-10-1381){ref-type="table-fn"}    1 nmol/L                                     0.88                0.68--1.06            6.72    0.04      0.66   0.42--0.79   4.59    0.03
  DHEAS, ng/mL (ln)   676 (221--934)     702 (239--921)                                             1 ln ng/mL                                   0.68                0.34--1.02            1.02    0.32      --     --           --      --
  IGF-1, ng/mL        91.6±38.4          96.6±32.6[\*\*](#tfn11-cia-10-1381){ref-type="table-fn"}   1 ng/mL                                      1.12                0.89--1.23            4.21    0.02      1.21   1.03--1.34   6.23    0.02
  E2, pg/mL           29.7±12.7          28.1±10.5                                                  1 pg/mL                                      0.94                0.84--1.06            0.78    0.43      --     --           --      --
  BMI, kg/m^2^        28.9±4.8           28.4±4.5                                                   1 kg/m^2^                                    0.89                0.78--0.96            2.34    0.10      --     --           --      --
  HbA~1c~, %          5.9±0.3            6.1±0.3[\*\*](#tfn11-cia-10-1381){ref-type="table-fn"}     1%                                           2.21                1.37--3.52            7.34    0.046     1.16   0.52--1.49   0.001   0.28
  Hypertension, yes   38 (19)            37 (30)                                                    Yes vs no                                    1.09                0.97--1.24            0.01    0.95      --     --           --      --
  MetS, yes           70 (23)            67 (53)                                                    Yes vs no                                    2.54                1.45--5.62            0.16    0.78      --     --           --      --
  CVD, yes            21 (7)             16 (13)                                                    Yes vs no                                    1.24                0.41--3.68            0.17    0.62      --     --           --      --
                      **n=36**           **n=48**                                                   **Men with prediabetes aged 60--80 years**                                                                                           
  Age, years          70±4               68±4                                                       1 year                                       0.97                0.92--1.03            0.43    0.50      --     --           --      --
  TT, nmol/L          10.2±3.7           12.8±3.8[\*](#tfn10-cia-10-1381){ref-type="table-fn"}      1 nmol/L                                     0.91                0.78--1.23            3.96    0.01      1.01   0.75--1.34   5.24    0.02
  cFT, nmol/L         0.298±0.08         0.322±0.07                                                 1 nmol/L                                     0.93                0.88--0.99            0.36    0.40      --     --           --      --
  DHEAS, ng/mL (ln)   411 (147--7,476)   439 (171--753)                                             1 ln ng/mL                                   4.28                2.34--6.45            12.23   \<0.001   1.98   1.43--4.12   3.90    0.03
  IGF-1, ng/mL        88.74±41.8         84.3±40.5[\*](#tfn10-cia-10-1381){ref-type="table-fn"}     1 ng/mL                                      1.21                0.89--1.76            3.28    0.10      --     --           --      --
  E2, pg/mL           33.7±8.9           31.2±9.8                                                   1 pg/mL                                      0.87                0.77--1.76            0.16    0.55      --     --           --      --
  BMI, kg/m^2^        31.2±4.4           30.2±4.3                                                   1 kg/m^2^                                    0.85                0.78--0.95            2.12    0.22      --     --           --      --
  HbA~1c~, %          5.8±0.3            6.4±0.3[\*\*](#tfn11-cia-10-1381){ref-type="table-fn"}     1%                                           1.98                1.68--2.56            0.64    0.44      --     --           --      --
  Hypertension, yes   67 (24)            60 (29)                                                    Yes vs no                                    0.88                0.48--1.98            0.16    0.94      --     --           --      --
  MetS, yes           86 (31)            85 (41)                                                    Yes vs no                                    2.21                1.45--5.61            0.36    0.58      --     --           --      --
  CVD, yes            42 (15)            35 (17)                                                    Yes vs no                                    1.45                0.97--4.21            0.02    1.45      --     --           --      --

**Notes:**

*P*\<0.05;

*P*\<0.01; data are presented as mean ± standard deviation of the mean, median (with lower and upper quartiles), or n (with %), where appropriate. All variables shown to be significant (*P*\<0.05) risk factors for the presence of AS in the univariable models were included in the multivariable models. AS was diagnosed if the Aging Males' Symptoms rating scale total score was ≥50 points. --Indicates no data available.

**Abbreviations:** AS, andropausal syndrome; BMI, body mass index; cFT, calculated free testosterone; CI, confidence interval; CVD, cardiovascular disease; DHEAS, dehydroepiandrosterone sulfate; E2, estradiol; HbA~1c~, glycated hemoglobin; IGF-1, insulin-like growth factor 1; ln, natural logarithm; MetS, metabolic syndrome; OR, odds ratio; TT, total testosterone; vs, versus.
